AR101891A1 - ANTI-VASA ANTIBODIES, AND METHODS OF PRODUCTION AND USE OF THE SAME - Google Patents

ANTI-VASA ANTIBODIES, AND METHODS OF PRODUCTION AND USE OF THE SAME

Info

Publication number
AR101891A1
AR101891A1 ARP150102964A ARP150102964A AR101891A1 AR 101891 A1 AR101891 A1 AR 101891A1 AR P150102964 A ARP150102964 A AR P150102964A AR P150102964 A ARP150102964 A AR P150102964A AR 101891 A1 AR101891 A1 AR 101891A1
Authority
AR
Argentina
Prior art keywords
vasa
sec
amino acid
acid sequence
group
Prior art date
Application number
ARP150102964A
Other languages
Spanish (es)
Original Assignee
Ovascience Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ovascience Inc filed Critical Ovascience Inc
Publication of AR101891A1 publication Critical patent/AR101891A1/en

Links

Landscapes

  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La divulgación además proporciona moléculas de ácido nucleico que codifican los mAb contra VASA, vectores de expresión, células huéspedes, métodos para la preparación de los mAb contra VASA, y métodos para la expresión de los mAb contra VASA. Finalmente, se divulgan métodos de uso de los mAb contra VASA para el aislamiento y/o la purificación de células que expresan VASA. Reivindicación 1: Un anticuerpo que se une específicamente a una proteína VASA humana que comprende una cadena pesada de inmunoglobulina y una cadena liviana de inmunoglobulina, donde la región variable de dicha cadena liviana comprende: (i) una región CDR1 que comprende una secuencia de aminoácidos seleccionada del grupo que consiste en SEC. ID. Nº 83 - 88; (ii) una región CDR2 que comprende una secuencia de aminoácidos seleccionada del grupo que consiste en SEC. ID. Nº 89 - 95; y/o (iii) una región CDR3 que comprende una secuencia de aminoácidos seleccionada del grupo que consiste en SEC. ID. Nº 96 - 104. Reivindicación 2: Un anticuerpo que se une específicamente a una proteína VASA humana que comprende una cadena pesada de inmunoglobulina y una cadena liviana de inmunoglobulina, donde la región variable de dicha cadena pesada comprende: (i) una región CDR1 que comprende una secuencia de aminoácidos seleccionada del grupo que consiste en SEC. ID. Nº 105 - 112; (ii) una región CDR2 que comprende una secuencia de aminoácidos seleccionada del grupo que consiste en SEC. ID. Nº 113 - 121; y/o (iii) una región CDR3 que comprende una secuencia de aminoácidos seleccionada del grupo que consiste en SEC. ID. Nº 122 - 131.The disclosure further provides nucleic acid molecules that encode mAbs against VASA, expression vectors, host cells, methods for the preparation of mAbs against VASA, and methods for the expression of mAbs against VASA. Finally, methods of using mAbs against VASA for the isolation and / or purification of cells expressing VASA are disclosed. Claim 1: An antibody that specifically binds to a human VASA protein comprising an immunoglobulin heavy chain and an immunoglobulin light chain, wherein the variable region of said light chain comprises: (i) a CDR1 region comprising an amino acid sequence selected from the group consisting of SEC. ID. No. 83-88; (ii) a CDR2 region comprising an amino acid sequence selected from the group consisting of SEC. ID. No. 89-95; and / or (iii) a CDR3 region comprising an amino acid sequence selected from the group consisting of SEC. ID. No. 96-104. Claim 2: An antibody that specifically binds to a human VASA protein comprising an immunoglobulin heavy chain and an immunoglobulin light chain, wherein the variable region of said heavy chain comprises: (i) a CDR1 region that it comprises an amino acid sequence selected from the group consisting of SEC. ID. No. 105-112; (ii) a CDR2 region comprising an amino acid sequence selected from the group consisting of SEC. ID. No. 113-121; and / or (iii) a CDR3 region comprising an amino acid sequence selected from the group consisting of SEC. ID. No. 122-131.

ARP150102964A 2014-09-16 2015-09-16 ANTI-VASA ANTIBODIES, AND METHODS OF PRODUCTION AND USE OF THE SAME AR101891A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201462051130P 2014-09-16 2014-09-16

Publications (1)

Publication Number Publication Date
AR101891A1 true AR101891A1 (en) 2017-01-18

Family

ID=58698591

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP150102964A AR101891A1 (en) 2014-09-16 2015-09-16 ANTI-VASA ANTIBODIES, AND METHODS OF PRODUCTION AND USE OF THE SAME

Country Status (2)

Country Link
AR (1) AR101891A1 (en)
MA (1) MA40086A1 (en)

Also Published As

Publication number Publication date
MA40086A1 (en) 2019-07-31

Similar Documents

Publication Publication Date Title
AR106184A1 (en) PD-1 BINDING PROTEINS AND THEIR METHODS OF USE
CL2019001926A1 (en) Anti-tigit antibodies and antigen-binding fragments; pharmaceutical composition comprising them; polynenucleotide encoding said antibody; vector comprising them, host cell; method of producing said antibody or antigen-binding fragment thereof; and use in the treatment of cancer. (Divisional Application 310-2017).
CO2018013500A2 (en) Anti-pd-l1 antibodies and uses thereof
AR102698A1 (en) ANTIBODIES AGAINST CD73 AND ITS USES
PE20240111A1 (en) BINDING MOLECULES TO PD-1 AND METHODS OF USE THEREOF
PE20190120A1 (en) BINDING MOLECULES TO BCMA AND METHODS OF USE OF THEM
PE20181044A1 (en) ANTI-PD-1 ANTIBODIES AND COMPOSITIONS
PE20190356A1 (en) CHEMERICAL RECEPTORS AND METHODS OF USE OF THE SAME
PE20180480A1 (en) FACTOR XI ANTIBODIES AND METHODS OF USE
PE20211291A1 (en) ANTI-OX40 ANTIBODIES AND METHODS OF USE
PE20171180A1 (en) ANTI-PD-1 ANTIBODIES AND THEIR METHODS OF USE
PE20190737A1 (en) ANTI-CD27 ANTIBODIES
EA201890302A1 (en) CHEMICAL ANTIGEN RECEPTORS BASED ON SINGLE-DOMAIN ANTIBODIES AND METHODS OF THEIR APPLICATION
AR101829A1 (en) CANCER TREATMENT USING A CLL-1 CHEMERIC ANTIGEN RECEIVER
AR095980A1 (en) SPECIFIC BIESPECTIFIC ANTIBODIES FOR FAP (FIBROBLASTIC ACTIVATION PROTEIN) AND DR5 (DEATH RECEIVER 5), SPECIFIC ANTIBODIES FOR DR5 AND METHODS OF USE
ES2687282T3 (en) ANTI-CD134 (OX40) humanized antibodies and their uses
CL2019000119A1 (en) Bispecific antibody binding proteins that specifically bind cd3 and cd123.
AR096617A1 (en) ANTI-TWEAKR ANTIBODIES AND THEIR USES
PE20181054A1 (en) HUMANIZED ANTI-CD19 ANTIBODIES AND METHODS OF USE
PE20151289A1 (en) ANTIBODIES THAT JOIN THE TL1A AND ITS USES
PE20180481A1 (en) UNION TO TAU ANTIBODIES
AR109683A1 (en) ANTIBODIES AGAINST FACTOR XI AND ITS USES
CL2017000912A1 (en) Antibodies that bind to ccr6 and its uses
ECSP18084153A (en) Humanized anti-BASIGIN antibodies and their use
EA201790236A1 (en) ANTIBODIES AGAINST VASA AND METHODS FOR THEIR PRODUCTION AND USE

Legal Events

Date Code Title Description
FB Suspension of granting procedure